Atypical HUS may become a diagnosis of inclusion

Blood

Volumn 125, Issue 23, 2015, Pages 3525-3526

  Sadler, J Evan ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT; COMPLEMENT COMPONENT C5A; COMPLEMENT FACTOR H; COMPLEMENT INHIBITOR; COMPLEMENT MEMBRANE ATTACK COMPLEX; ECULIZUMAB; MEMBRANE COFACTOR PROTEIN; SHIGA TOXIN; VON WILLEBRAND FACTOR CLEAVING PROTEINASE;

COMPLEMENT ACTIVATION; COMPLEMENT ALTERNATIVE PATHWAY; END STAGE RENAL DISEASE; ESCHERICHIA COLI; GENE MUTATION; HEMOLYTIC UREMIC SYNDROME; HUMAN; NOTE; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOTIC THROMBOCYTOPENIC PURPURA; ATYPICAL HEMOLYTIC UREMIC SYNDROME; BLOOD; FEMALE; MALE;

ATYPICAL HEMOLYTIC UREMIC SYNDROME; FEMALE; HUMANS; MALE;

EID: 84930959416     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-04-640656     Document Type: Note

References (7)

1. Gavriilaki E, Yuan X, Ye Z, et al. Modified Ham test for atypical hemolytic uremic syndrome. Blood. 2015; 125(23):3637-3646.
2. Legendre CM, Licht C, Muus P, et al. Terminal complement inhibitor eculizumab in atypical hemolyticuremic syndrome. N Engl J Med. 2013;368(23): 2169-2181.
3. Cataland SR, Holers VM, Geyer S, Yang S, Wu HM. Biomarkers of terminal complement activation confirm the diagnosis of aHUS and differentiate aHUS from TTP. Blood. 2014;123(24):3733-3738.
4. Noris M, Galbusera M, Gastoldi S, et al. Dynamics of complement activation in aHUS and how to monitor eculizumab therapy. Blood. 2014;124(11):1715-1726.
5. Volokhina EB, Westra D, van der Velden TJ, van de Kar NC, Mollnes TE, van den Heuvel LP. Complement activation patterns in atypical hemolytic uremic syndrome during acute phase and in remission [published online ahead of print July 31, 2014]. Clin Exp Immunol. doi: 10.1111/cei.12426.
6. Ruiz-Torres MP, Casiraghi F, Galbusera M, et al. Complement activation: the missing link between ADAMTS-13 deficiency and microvascular thrombosis of thrombotic microangiopathies. Thromb Haemost. 2005;93(3):443-452.
7. Sullivan M, Erlic Z, Hoffmann MM, et al. Epidemiological approach to identifying genetic predispositions for atypical hemolytic uremic syndrome. Ann Hum Genet. 2010;74(1):17-26.